EditorialTo Palivizumab or not to Palivizumab – that is the question
References (8)
- et al.
A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis
Journal of Managed Care Pharmacy: JMCP
(2010) - Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory...
- et al.
Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria
The Pediatric Infectious Disease Journal
(2012) - et al.
Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses
Health Technology Assessment
(2011)
There are more references available in the full text version of this article.
Cited by (2)
Copyright © 2013 Elsevier Ltd. All rights reserved.